Transforming into a Strong Chemical Company and Achieving Profitable Growth under the Sixth Medium-Term Management Plan
First written in FY2016. 20 of 31 entries say "Restated". Latest entry: 2026-08-07.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- 2026-08-07SoftenedEarnings
「通期 150,000 △3.2 14,200 △25.6 13,300 △38.8 ― ― ―」
2027年3月期の通期営業利益予想を142億円とし、従来予想から下方修正した。親会社株主に帰属する当期純利益は、無機化学事業構造改革に伴う特別損失の見積りが困難として公表していない。 - FY2026AdvancedAnnual report
「Fiscal 2023 results (A) Medium-Term Management Plan “Vision 2030 Stage II” Fiscal 2024 results Fiscal 2025 results Fiscal 2026 (B) (B)/(A) Net sales ¥138.4 billion ¥145.1 billion ¥154.8 billion ¥160.7 billion 1.2x Operating profit ¥11.4 billion ¥10.4 billion ¥19.0 billion ¥19.8 billion 1.7x Ordinary profit ¥14.8 billion ¥11.3 billion ¥21.7 billion ¥19.3 billion 1.3x Net income attributable to owners of the parent ¥7.9 billion ¥8.4 billion ¥16.6 billion ¥13.6 billion 1.7x Operating margin 8.3% 7.2% 12.3% 12.3% 1.5x ROE 7.9% 7.6% 13.7% 11.2% 1.4x」
Fiscal 2025 results under Stage II included net sales of ¥154.8 billion, operating profit of ¥19.0 billion, net income attributable to owners of the parent of ¥16.6 billion and ROE of 13.7%. Net income and ROE exceeded the fiscal 2026 plan, while net sales and operating profit were below plan, providing measurable progress toward the final year of the plan. - FY2025RaisedAnnual report
「Fiscal 2023 results (A) New Medium-Term Management Plan “Vision 2030 Stage II” Fiscal 2024 results Fiscal 2026 (B) (B)/(A) Net sales ¥138.4 billion ¥145.1 billion ¥160.7 billion 1.2x Operating profit ¥11.4 billion ¥10.4 billion ¥19.8 billion 1.7x Ordinary profit ¥14.8 billion ¥11.3 billion ¥19.3 billion 1.3x Net income attributable to owners of the parent ¥7.9 billion ¥8.4 billion ¥13.6 billion 1.7x Operating margin 8.3% 7.2% 12.3% 1.5x ROE 7.9% 7.6% 11.2% 1.4x」
Fiscal 2024 results under Stage II were disclosed, with fiscal 2026 targets of ¥19.8 billion in operating profit and 11.2% ROE. The figures in the plan table are higher than the previously disclosed Stage II targets of at least ¥19.0 billion in operating profit and at least 10% ROE. - FY2025-H1RestatedAnnual report
「Under the long-term vision “Vision 2030—Originality, Acceleration, Globalization. Changing Lives through the Power of Chemistry,” the Group is pursuing Vision 2030 Stage II, its three-year medium-term management plan for fiscal 2024 through fiscal 2026, strengthening business activities founded on sustainability and aiming to enhance corporate value.」
Under Vision 2030 Stage II, the Group reaffirmed its policy of strengthening business activities founded on sustainability and enhancing corporate value. - FY2024ReframedAnnual report
「The Group is implementing the long-term vision “Vision 2030” and the medium-term management plan based on it, “Vision 2030 Stage II” for fiscal 2024–2026.」
The Group transitioned from Vision 2030 Stage I to Stage II, covering fiscal 2024–2026. Stage II sets targets including consolidated operating profit of at least ¥19.0 billion, ROE of at least 10% and a consolidated dividend payout ratio of 40% for fiscal 2026, with research and technology development capabilities, globalization, ROIC management and shareholder returns as key initiatives. - FY2024-Q3RestatedAnnual report
「During the first 9 months of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group reaffirmed that there were no material changes or new issues concerning the business and financial matters it needs to address. - FY2024-Q2RestatedAnnual report
「Under the long-term vision “Vision 2030—Originality, Acceleration, Globalization. Changing Lives through the Power of Chemistry,” the Group is pursuing Vision 2030 Stage I, its three-year medium-term management plan for fiscal 2021 through fiscal 2023, and aims to create sustainable corporate value by strengthening management from ESG and SDGs perspectives and specifying its targets.」
The Group continues to strengthen management from ESG and SDGs perspectives and specify its targets under Vision 2030 and Vision 2030 Stage I. - FY2023SoftenedAnnual report
「Fiscal 2021 actual, fiscal 2022 actual, fiscal 2023 forecast: net sales ¥110.9 billion, ¥131.2 billion, ¥147.0 billion; operating profit ¥11.5 billion, ¥8.6 billion, ¥11.0 billion; ordinary profit ¥13.2 billion, ¥10.3 billion, ¥10.5 billion; net income attributable to owners of the parent ¥11.6 billion, ¥6.9 billion, ¥7.5 billion; operating margin 10%, 7%, 7%; ROE 14%, 7%, at least 7%.」
The Group updated fiscal 2022 actual results and its fiscal 2023 forecast for Vision 2030 Stage I. The sales forecast was raised to ¥147.0 billion, while targets for operating profit of ¥11.0 billion, operating margin of 7% and ROE of at least 7% were reduced from the previous fiscal 2023 plan. - FY2023-Q3RestatedAnnual report
「During the first 9 months of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group reaffirmed that there were no material changes or new issues concerning the business and financial matters it needs to address. - FY2023-Q2RestatedAnnual report
「Under the long-term vision “Vision 2030—Originality, Acceleration, Globalization. Changing Lives through the Power of Chemistry,” the Group is pursuing Vision 2030 Stage I, its three-year medium-term management plan for fiscal 2021 through fiscal 2023, and aims to create sustainable corporate value by strengthening management from ESG and SDGs perspectives and giving its targets greater specificity.」
The Group reaffirmed its policy of strengthening management from ESG and SDGs perspectives and specifying its targets under Vision 2030 and Vision 2030 Stage I, with the aim of creating sustainable corporate value. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group reaffirmed that there were no material changes or new issues concerning the business and financial matters it needs to address. - FY2022AdvancedAnnual report
「Fiscal 2021 actual: net sales ¥110.9 billion; operating profit ¥11.5 billion; ordinary profit ¥13.2 billion; profit attributable to owners of parent ¥11.6 billion; operating margin 10%; ROE 14%. Fiscal 2023 plan: net sales ¥125.0 billion; operating profit ¥16.6 billion; ordinary profit ¥15.8 billion; profit attributable to owners of parent ¥12.4 billion; operating margin 13%; ROE at least 10%.」
The Group disclosed fiscal 2021 actual results alongside the fiscal 2023 plan for Vision 2030 Stage I, making progress measurable through net sales of ¥110.9 billion, operating profit of ¥11.5 billion and ROE of 14% in the first year. - FY2022-Q2RestatedAnnual report
「Against this backdrop, the Group adopted the long-term vision “Vision 2030: Creativity, Acceleration and Globalization. Changing Lives through the Power of Chemistry,” announced the three-year medium-term management plan “Vision 2030 Stage I” for fiscal 2021–2023, and is pursuing initiatives aimed at creating sustainable corporate value by strengthening management from ESG and SDGs perspectives.」
Under Vision 2030 and Vision 2030 Stage I for fiscal 2021–2023, the Group is strengthening management from ESG and SDGs perspectives and pursuing sustainable corporate value creation. - FY2021ReframedAnnual report
「The Group has formulated the long-term vision “Vision 2030” and the new medium-term management plan based on it, “Vision 2030 Stage I” for fiscal 2021–2023.」
The Group transitioned from the Seventh Medium-Term Management Plan to the long-term vision through 2030 and the new medium-term management plan for fiscal 2021–2023, “Vision 2030 Stage I.” Targets include consolidated net sales of more than ¥200.0 billion, a consolidated operating margin of at least 15% and ROE of at least 10% by 2030, and consolidated net sales of more than ¥125.0 billion, an operating margin of at least 13% and ROE of at least 10% for fiscal 2023. - FY2021-Q3RestatedAnnual report
「During the first 9 months of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group states that there were no material changes or new issues among the business and financial matters requiring attention. - FY2021-Q2RestatedAnnual report
「During the first half of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group states that there were no material changes or new issues among the business and financial matters requiring attention. - FY2021-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no material changes to, or newly arising, business or financial challenges requiring action by the Group.」
The Group states that there were no material changes or new issues among the business and financial matters requiring attention. - FY2020RestatedAnnual report
「In fiscal 2020, the final year of the plan, the further spread and prolonged duration of the novel coronavirus pandemic are expected to affect performance.」
The targets and policies for the final year of the 7th Medium-Term Management Plan were maintained, although fiscal 2019 performance fell below plan targets because the business environment deteriorated more than expected. - FY2020-Q3RestatedAnnual report
「Against this backdrop, as the Group entered the second year of the Seventh Medium-Term Management Plan toward its centenary in 2020, it has been advancing growth initiatives while firmly strengthening the earnings base of its existing businesses.」
In the second year of the 7th Medium-Term Management Plan, the Group continued to strengthen the earnings base of existing businesses and pursue growth initiatives. - FY2020-Q2RestatedAnnual report
「Against this backdrop, as the Group entered the second year of the Seventh Medium-Term Management Plan toward its centenary in 2020, it has been advancing growth initiatives while firmly strengthening the earnings base of its existing businesses.」
In the second year of the Seventh Medium-Term Management Plan, the Group reaffirmed its focus on strengthening the earnings base of existing businesses and pursuing growth initiatives through 2020. No new numerical targets or specific milestones are stated. - FY2019-Q3RestatedAnnual report
「Against this backdrop, the Group launched the Seventh Medium-Term Management Plan toward its centenary in 2020. Under the plan, it is strengthening initiatives to shift toward growth while firmly securing the foundations of its existing businesses.」
Under the Seventh Medium-Term Management Plan through 2020, the Group continues to protect existing businesses and pursue new growth. No new numerical targets or individual milestones are stated. - FY2019-Q2RestatedAnnual report
「Against this backdrop, the Group launched the Seventh Medium-Term Management Plan in the current fiscal year to strengthen initiatives aimed at growth while firmly securing the foundations of its existing businesses ahead of its centenary in 2020.」
Under the Seventh Medium-Term Management Plan, the Group reaffirmed its policy of defending existing businesses and advancing growth initiatives toward 2020. No new numerical targets or specific milestones are stated. - FY2018ReframedAnnual report
「The Group has formulated the “Seventh Medium-Term Management Plan (Fiscal 2018–Fiscal 2020)” covering the three years from fiscal 2018 through fiscal 2020, with a view to 2020.」
Following the completion of the Sixth Medium-Term Management Plan, the Group moved to the Seventh Medium-Term Management Plan. Numerical targets included consolidated net sales of ¥131.0 billion, consolidated operating profit of ¥12.1 billion and ROE of 10% for fiscal 2020, combining the defense and growth of existing businesses. - FY2018-Q3RestatedAnnual report
「Against this backdrop, as the Group entered the final year of the Sixth Medium-Term Management Plan, its inorganic chemicals business continued working to develop technologies and expand sales channels in high-value-added fields, while its organic chemicals business continued efforts to ensure the launch of new agrochemicals and strengthen overseas sales bases.」
In the final year of the Sixth Medium-Term Management Plan, the Group continued efforts to add value in its inorganic chemicals business and to launch new agrochemicals and strengthen overseas sales bases in its organic chemicals business. - FY2018-Q2RestatedAnnual report
「Against this backdrop, as the Group entered the final year of the Sixth Medium-Term Management Plan, its inorganic chemicals business continued working to develop technologies and expand sales channels in high-value-added fields, while its organic chemicals business continued efforts to ensure the launch of new agrochemicals and strengthen overseas sales bases.」
In the final year of the Sixth Medium-Term Management Plan, the Group continued efforts to add value and expand sales channels in inorganic chemicals, and to launch new agrochemicals and strengthen overseas sales bases in organic chemicals. - FY2017RestatedAnnual report
「To realize the corporate group envisioned for 2020, the centenary of its founding, the Group has been implementing the Sixth Medium-Term Management Plan as a three-year plan since fiscal 2015. Under the theme of “Transformation and Execution toward a Strong Chemical Company,” all Group companies have worked together on initiatives centered on strengthening existing businesses and reinforcing the foundations for growth.」
The Group reaffirmed the framework of the Sixth Medium-Term Management Plan through 2020, centered on strengthening existing businesses and reinforcing the foundations for growth. Although operating profit in the second year fell short of the plan’s target, no withdrawal or revision of the plan is stated. - FY2017-Q3RestatedAnnual report
「Against this backdrop, based on the basic policies of the Sixth Medium-Term Management Plan, the Group steadily advanced efforts to strengthen its existing businesses, including expanding overseas sales and increasing sales of high-value-added products, as well as research and development aimed at building the foundations for future growth.」
The Group continues to strengthen existing businesses and build the foundations for growth through research and development under the Sixth Medium-Term Management Plan. - FY2017-Q2RestatedAnnual report
「Against this backdrop, based on the basic policies of the Sixth Medium-Term Management Plan, the Group steadily advanced efforts to strengthen its existing businesses, including expanding overseas sales and increasing sales of high-value-added products, as well as research and development aimed at building the foundations for future growth, but」
The Group continues to strengthen existing businesses and build the foundations for future growth under the Sixth Medium-Term Management Plan. No specific new milestone is stated. - FY2016First statedAnnual report
「Under the theme of “Transformation and Execution Toward a Strong Chemical Company,” the Sixth Medium-Term Management Plan focuses on strengthening existing businesses and the foundations for growth. The Group is working together to stabilize performance toward 2020, its centennial year, and achieve its primary objective of establishing a path to profitable growth.」
The primary objective is to stabilize performance toward 2020 and achieve profitable growth by strengthening existing businesses and the foundations for growth.